$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222020255 Filed on July 25, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$2.400M	$3.279M	$3.240M
YoY Change	-5.87%	72.72%	6.24%
Cost Of Revenue	$998.3K	$2.108M	$1.905M
YoY Change	-21.33%	99.44%	14.05%
Gross Profit	$1.402M	$1.171M	$1.336M
YoY Change	9.44%	39.16%	-3.21%
Gross Profit Margin	58.41%	35.71%	41.22%
Selling, General & Admin	$1.809M	$2.274M	$2.304M
YoY Change	-29.77%	4.03%	13.51%
% of Gross Profit	129.03%	194.21%	172.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$17.53K	$19.72K	$3.970K
YoY Change	901.71%	463.43%
% of Gross Profit	1.25%	1.68%	0.3%
Operating Expenses	$1.809M	$2.274M	$2.304M
YoY Change	-29.77%	-33.33%	13.51%
Operating Profit	-$407.0K	-$1.103M	-$968.6K
YoY Change	-68.56%	-57.07%	49.01%
Interest Expense	$130.1K	$9.155K	-$1.360K
YoY Change	-2415.07%	5.38%	-86.4%
% of Operating Profit
Other Income/Expense, Net	-$121.7K	-$9.155K	$2.736K
YoY Change	2064.91%
Pretax Income	-$528.7K	-$1.112M	-$965.8K
YoY Change	-59.38%	-56.86%	48.59%
Income Tax
% Of Pretax Income
Net Earnings	-$503.0K	-$1.084M	-$965.8K
YoY Change	-61.36%	-57.97%	48.24%
Net Earnings / Revenue	-20.96%	-33.05%	-29.81%
Basic Earnings Per Share	-$0.06	-$0.13	-$0.12
Diluted Earnings Per Share	-$0.06	-$0.13	-$117.4K
COMMON SHARES
Basic Shares Outstanding	8.181M shares	8.181M shares	8.178M shares
Diluted Shares Outstanding	551.7K shares	545.4K shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$321.7K	$962.2K	$1.871M
YoY Change	-90.99%	-78.71%	-64.09%
Cash & Equivalents	$300.0K	$1.000M	$1.871M
Short-Term Investments
Other Short-Term Assets	$249.8K	$363.6K	$411.6K
YoY Change	-51.38%	-2.52%	-10.53%
Inventory	$75.95K	$127.1K	$274.0K
Prepaid Expenses	$249.8K	$363.6K
Receivables	$850.3K	$1.019M	$1.041M
Other Receivables	$875.3K	$0.00	$0.00
Total Short-Term Assets	$2.373M	$3.347M	$3.597M
YoY Change	-54.27%	-48.79%	-60.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$68.04K	$70.86K	$1.252M
YoY Change	-77.56%	-79.05%	140.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.03K	$49.03K	$49.03K
YoY Change	126.57%	126.57%	145.15%
Total Long-Term Assets	$2.316M	$2.325M	$2.243M
YoY Change	613.07%	546.11%	323.23%
TOTAL ASSETS
Total Short-Term Assets	$2.373M	$3.347M	$3.597M
Total Long-Term Assets	$2.316M	$2.325M	$2.243M
Total Assets	$4.689M	$5.672M	$5.840M
YoY Change	-14.96%	-17.74%	-39.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$744.4K	$1.195M	$908.5K
YoY Change	170.48%	609.86%	145.54%
Accrued Expenses	$312.1K	$437.3K	$520.2K
YoY Change	-17.8%	-6.5%	-18.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$166.7K	$166.7K	$166.7K
YoY Change		-25.92%	-27.53%
Total Short-Term Liabilities	$2.061M	$2.546M	$1.596M
YoY Change	214.78%	195.73%	28.74%
LONG-TERM LIABILITIES
Long-Term Debt	$333.3K	$333.3K	$333.3K
YoY Change
Other Long-Term Liabilities	$938.0K	$988.2K	$1.023M
YoY Change	287.68%	298.46%	309.19%
Total Long-Term Liabilities	$938.0K	$988.2K	$1.356M
YoY Change	287.68%	298.46%	442.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.061M	$2.546M	$1.596M
Total Long-Term Liabilities	$938.0K	$988.2K	$1.356M
Total Liabilities	$3.333M	$3.868M	$2.970M
YoY Change	271.62%	248.76%	99.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.80M	-$18.30M
YoY Change
Common Stock	$83.00	$82.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.399M	$1.821M	$2.870M
YoY Change
Total Liabilities & Shareholders Equity	$4.689M	$5.672M	$5.840M
YoY Change	-14.96%	-17.74%	-39.73%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$503.0K	-$1.084M	-$965.8K
YoY Change	-61.36%	-57.97%	48.24%
Depreciation, Depletion And Amortization	$17.53K	$19.72K	$3.970K
YoY Change	901.71%	463.43%
Cash From Operating Activities	-$576.9K	-$1.178M	-$1.001M
YoY Change	-21.83%	70.41%	40.95%
INVESTING ACTIVITIES
Capital Expenditures	-$55.73K	-$280.2K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$23.00K
YoY Change
Cash From Investing Activities	-$55.73K	-$280.2K	$23.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.860K	550.0K	-274.1K
YoY Change	-96.26%	30120.33%
NET CHANGE
Cash From Operating Activities	-576.9K	-1.178M	-1.001M
Cash From Investing Activities	-55.73K	-280.2K	23.00K
Cash From Financing Activities	-7.860K	550.0K	-274.1K
Net Change In Cash	-640.5K	-908.4K	-1.252M
YoY Change	-32.44%	31.73%
FREE CASH FLOW
Cash From Operating Activities	-$576.9K	-$1.178M	-$1.001M
Capital Expenditures	-$55.73K	-$280.2K
Free Cash Flow	-$521.2K	-$898.1K
YoY Change	-29.39%	29.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Notes Payable NotesPayable		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2022Q2	MEDS	Loss On Inventory Investment LossOnInventoryInvestment		usd
	MEDS	Loss On Inventory Investment LossOnInventoryInvestment		usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q2	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash		usd
	MEDS	Loss On Inventory Investments LossOnInventoryInvestments		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Profit Loss ProfitLoss	-2078097	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced		usd
	MEDS	Increase Decrease In Inventory Deposits IncreaseDecreaseInInventoryDeposits		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1147222	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1233033	usd
CY2022Q2	us-gaap	Assets Assets	5672460	usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39199
	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	261-0281
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MEDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8181041	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962227	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3122578	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1019068	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978973	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	127139	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	56279	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	875321	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	363623	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	216414	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	3347378	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	4374244	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70857	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98751	usd
CY2022Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1057972	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	60136	usd
CY2021Q4	us-gaap	Assets Assets	5766164	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1195192	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	477028	usd
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8166457	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	437285	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	270437	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14199	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2022Q2	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	550000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	183066	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178561	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	166667	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2546409	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	926026	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	988185	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069965	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	333333	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3867927	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1995991	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8181041	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8181041	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8166457	shares
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20112485	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20017528	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18291347	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16247437	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1821220	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3770173	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-16687	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5672460	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5766164	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3278729	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1898254	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6519001	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4951489	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2107815	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2569588	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2071678	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1056863	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4012384	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3213843	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2726787	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1170914	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	841391	usd
	us-gaap	Gross Profit GrossProfit	2506617	usd
	us-gaap	Gross Profit GrossProfit	2224702	usd
CY2021Q2	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1225141	usd
	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1225141	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	1178124	usd
CY2021Q2	us-gaap	Salaries And Wages SalariesAndWages	922787	usd
	us-gaap	Salaries And Wages SalariesAndWages	2248082	usd
	us-gaap	Salaries And Wages SalariesAndWages	1862421	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	111057	usd
CY2021Q2	us-gaap	Professional Fees ProfessionalFees	286987	usd
	us-gaap	Professional Fees ProfessionalFees	212066	usd
	us-gaap	Professional Fees ProfessionalFees	551806	usd
CY2022Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	139858	usd
CY2021Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	203712	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	376079	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	363759	usd
CY2022Q2	MEDS	Technology Expense TechnologyExpense	298062	usd
CY2021Q2	MEDS	Technology Expense TechnologyExpense	124583	usd
	MEDS	Technology Expense TechnologyExpense	543847	usd
	MEDS	Technology Expense TechnologyExpense	339473	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	546919	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	647769	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1198221	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1095945	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2274020	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	3410979	usd
	us-gaap	Operating Expenses OperatingExpenses	4578295	usd
	us-gaap	Operating Expenses OperatingExpenses	5438545	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1103106	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4100	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	9155	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	8688	usd
	us-gaap	Interest Expense InterestExpense	10519	usd
	us-gaap	Interest Expense InterestExpense	15952	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2578276	usd
	us-gaap	Profit Loss ProfitLoss	-2078097	usd
	us-gaap	Profit Loss ProfitLoss	-3229795	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1083763	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2578276	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2043910	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3229795	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-28498	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34187	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1083763	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2578276	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32783	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-965836	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12222	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	16994	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8201624	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2043910	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3229795	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100416	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1821	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	70860	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1118637	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61392	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2578276	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5786977	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32083	usd
CY2022Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8181041	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8122206	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8179591	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8107864	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8679158	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	98247	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	75738	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-651519	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
	us-gaap	Profit Loss ProfitLoss	-2078097	usd
	us-gaap	Profit Loss ProfitLoss	-3229795	usd
	us-gaap	Depreciation Depreciation	8994	usd
	us-gaap	Depreciation Depreciation	3500	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	49777	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	137130	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	44305	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	198663	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-98841	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-10000	usd
	MEDS	Loss On Inventory Investments LossOnInventoryInvestments	1225141	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4100	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	85811	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	64150	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14700	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-58746	usd
	MEDS	Increase Decrease In Inventory Deposits IncreaseDecreaseInInventoryDeposits	875321	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2160351	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	688994	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-84250	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1399595	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	221782	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5919578	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	962227	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4519983	usd
	us-gaap	Interest Paid Net InterestPaidNet	3328	usd
	us-gaap	Interest Paid Net InterestPaidNet	4702	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6425	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-77275	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-63829	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	718164	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-88455	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-53506	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	157793	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	14199	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	-10000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2179054	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1401416	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
	us-gaap	Payments For Software PaymentsForSoftware	280172	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-257172	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	550000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1821	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	275875	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1821	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest	792500	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	98841	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	10000	usd
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	26924	usd
CY2022Q2	MEDS	Number Of Options Outstanding NumberOfOptionsOutstanding	408317	shares
CY2022Q2	MEDS	Initial Lease Liability InitialLeaseLiability	15000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2578276	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	137130	usd
CY2022Q2	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.06
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding	P1Y3D
	us-gaap	Profit Loss ProfitLoss	-3229795	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1083763	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2578276	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2043910	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3229795	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8181041	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8122206	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8179591	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8107864	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18300000	usd
CY2022Q2	MEDS	Working Capital WorkingCapital	800000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1000000	usd
CY2022Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14700	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	500000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	44535	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.32
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P0Y11M12D
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	208078	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3027	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	3.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14584	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.06
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	26924	shares
CY2022Q2	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	39578	usd
CY2022Q2	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber	26924	shares
CY2022Q2	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	0.06
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P1Y3D
CY2022Q2	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1	39578	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	51875	usd
CY2022Q2	MEDS	Increase In Lease Liability IncreaseInLeaseLiability	977220	usd
CY2022Q2	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6519001	usd
	us-gaap	Gross Profit GrossProfit	2506617	usd
CY2022Q2	us-gaap	Assets Assets	5672460	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_801_eus-gaap--LossContingencyDisclosures_zGm5uZBBwLx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"/>NOTE 8 – <span id="xdx_828_zEzJPIbAP3R4">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $<span id="xdx_900_ecustom--DownPayment_pp0p0_c20200701__20200731__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_z6Ru5ilOCfj6">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Studebaker would deliver <span id="xdx_909_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zmXH05X7buXi">180,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">boxes of nitrile gloves by August 14, 2020. Integra wired the $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_znGlvAUoZEd8">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. Studebaker then filed an answer and affirmative defenses, and we filed a motion to strike their affirmative defenses. The court has not yet ruled, but the discovery phase of the litigation has commenced; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_905_ecustom--LossOnInventoryInvestment_pp0p0_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zj6M9UbA7k1g" title="Loss on inventory investment">500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $<span id="xdx_903_ecustom--DownPayment_pp0p0_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_z2vZDknbTMO3" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_90B_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zi9PLTkeORU8" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. Integra wired the $<span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_pp0p0" title="Loss contingency, damages sought, value">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $<span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember_z5sObRWg37C9" title="Loss contingency, damages sought, value">581,250</span> and Crecom has acknowledged that Integra is entitled to a refund, but to date Crecom has failed to return Integra’s money. In February 2021, Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. Crecom filed an appearance on March 1, 2021. In April 2021, an Application for Summary Judgment was filed with the court, and on May 25, 2021, the Court extracted the sealed application, and a copy thereof was served on Crecom’s attorneys and Crecom, 14 days later, filed an Affidavit in Reply with the court alleging that there are issues to be tried and that this case must go to a full trial. On June 28, 2021, the court directed both parties to file their written submissions/arguments in relation to the application for summary judgment on or before July 12, 2021 and scheduled a hearing thereon for August 26, 2021. At the final hearing on October 18, 2021, the ruling for the summary judgment was denied and a trial date is pending. The Company believes that it will prevail in the lawsuit filed; but the steps to enforce a judgment in Malaysia, if any, may be cumbersome, time consuming or costly. The Company cannot determine the timing of the judgment, nor the amount ultimately collected. At June 30, 2021, the $<span id="xdx_908_ecustom--LossOnInventoryInvestment_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zBYCLl9tLedd" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930_z7dpezzjJvZ8" title="Debt instrument face amount">630,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_906_ecustom--AttorneyFees_pp0p0_c20220101__20220630_zSM0seBCIWyc">630,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Waxman’s personal guaranty confirmed that GSG owed Integra $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--WaxmanMember_zCw6zXCSLsVa">630,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. On September 30, 2021, the $<span id="xdx_90E_ecustom--BadDebtExpenses_pp0p0_c20210101__20210930_zZSt6svLQeHc">630,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_904_ecustom--AttorneyFees_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__custom--WaxmanMember_zVX9GWYYoKg8">743,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. In June 2022, the Company received a $<span id="xdx_904_ecustom--PaymentReceived_pp0p0_c20220101__20220630__dei--LegalEntityAxis__custom--GSGPPELLCMember_zPPKXDKptzGi" title="Payment received">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment from GSG and recorded a credit to Bad Debt Expense. Future payments will also be recorded as a credit to Bad Debt Expense, less applicable interest and recovered legal fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jain, et al., v. Memantine, et al. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $<span id="xdx_90F_eus-gaap--LossContingencyDamagesPaidValue_pp0p0_c20210501__20210514_zmEsltLo00pl" title="Compensatory amount value">425,000</span> in compensatory damages, treble damages, punitive damages, and fees and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and Trxade Group has been reached and signed. This settlement involves no admission of liability and a full and complete release of all actions after a lump-sum payment of $<span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pp0p0_c20220201__20220228_zxAjzJE47r0i" title="Settlement payment amount">225,000</span> is made. Because the complaint purports to be a derivative action, court approval was required, which approval was received on March 14, 2022. As a result of the settlement, the Plaintiff’s dismissed their lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
	MEDS	Attorney Fees AttorneyFees	630000	usd
	MEDS	Bad Debt Expenses BadDebtExpenses	630000	usd
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	425000	usd
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	225000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	289395	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	298085	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	307027	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	316238	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	188913	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	77214	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1476872	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	320274	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1156598	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	183066	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	974783	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	13402	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	85811	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	64150	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	77275	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	63829	usd
	us-gaap	Profit Loss ProfitLoss	-2078097	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4012384	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4951489	usd
	us-gaap	Gross Profit GrossProfit	2224702	usd
CY2021Q2	us-gaap	Assets Assets	6896030	usd
	us-gaap	Profit Loss ProfitLoss	-3229795	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2726787	usd

Files In Submission

Name	View Source	Status
0001493152-22-020255-index-headers.html	Edgar Link	pending
0001493152-22-020255-index.html	Edgar Link	pending
0001493152-22-020255.txt	Edgar Link	pending
0001493152-22-020255-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-4_001.jpg	Edgar Link	pending
ex10-4_002.jpg	Edgar Link	pending
ex10-4_003.jpg	Edgar Link	pending
ex10-4_004.jpg	Edgar Link	pending
ex10-4_005.jpg	Edgar Link	pending
ex10-4_006.jpg	Edgar Link	pending
ex10-4_007.jpg	Edgar Link	pending
ex10-4_008.jpg	Edgar Link	pending
ex10-4_009.jpg	Edgar Link	pending
ex10-4_010.jpg	Edgar Link	pending
ex10-4_011.jpg	Edgar Link	pending
ex10-4_012.jpg	Edgar Link	pending
ex10-4_013.jpg	Edgar Link	pending
ex10-4_014.jpg	Edgar Link	pending
ex10-4_015.jpg	Edgar Link	pending
ex10-4_016.jpg	Edgar Link	pending
ex10-4_017.jpg	Edgar Link	pending
ex10-4_018.jpg	Edgar Link	pending
ex10-4_019.jpg	Edgar Link	pending
ex10-4_020.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
form10-q_002.jpg	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
meds-20220630.xsd	Edgar Link	pending
meds-20220630_cal.xml	Edgar Link	unprocessable
meds-20220630_def.xml	Edgar Link	unprocessable
meds-20220630_lab.xml	Edgar Link	unprocessable
meds-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2022 Q3 Form 10-Q Financial Statement

#000149315222020255 Filed on July 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2022 Q3 Form 10-Q Financial Statement

#000149315222020255 Filed on July 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx